[Hypersexuality Induced by Aripiprazole].

Psychiatr Prax

Vinzenz von Paul Hospital, Rottweil.

Published: January 2020

Hypersexual behavior can be assumed as a rare side effect of treatment with aripiprazole and is possibly due to partial agonism on dopamine receptors or partial agonism on 5-HT receptors and 5 HT antagonism.

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0941-3874DOI Listing

Publication Analysis

Top Keywords

partial agonism
8
[hypersexuality induced
4
induced aripiprazole]
4
aripiprazole] hypersexual
4
hypersexual behavior
4
behavior assumed
4
assumed rare
4
rare side
4
side treatment
4
treatment aripiprazole
4

Similar Publications

Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation.

Mol Metab

January 2025

Section of Endocrinology and Investigative Medicine, Imperial College London, United Kingdom. Electronic address:

Objective: There is renewed interest in targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) for treatment of obesity and type 2 diabetes. G-protein coupled receptor desensitisation is suggested to reduce the long-term efficacy of glucagon-like-peptide 1 receptor (GLP-1R) agonists and may similarly affect the efficacy of GIPR agonists. We explored the extent of pancreatic GIPR functional desensitisation with sustained agonist exposure.

View Article and Find Full Text PDF

Buprenorphine: An anesthesia-centric review.

J Opioid Manag

January 2025

Harvard Medical School; MGH/Harvard Center for Addiction Medicine, Massachusetts General Hospital; Addiction Leadership, Charlestown Community Health Care Center for Pain Management; HOME BASE Veterans and Family Care, Boston, Massachusetts.

Buprenorphine was synthesized in the 1960s as a result of a search for a safe and effective opioid analgesic. Present formulations of buprenorphine are approved for the treatment of both acute and chronic pain. Its long duration of action, high affinity, and partial agonism at the µ-opioid receptor have established it as a mainstay treatment for opioid use disorder (OUD).

View Article and Find Full Text PDF

Purpose: Activating T cell costimulatory receptors is a promising approach for cancer immunotherapy. In preclinical work, adding an OX40 agonist to in situ vaccination (ISV) with SD101, a TLR9 agonist, was curative in a mouse model of lymphoma. We sought to test this combination in a Phase I clinical trial for patients with low-grade B cell lymphoma.

View Article and Find Full Text PDF

Background: S-pindolol has metabolic effects of potential benefit in cancer cachexia: reduced catabolism through nonselective β-blockade; increased anabolism through partial β2 receptor agonism; and increased appetite and reduced fatigue through central 5-hydroxytryptamine/serotonin receptor activity. A Phase 2a clinical trial demonstrated that S-pindolol can reverse weight loss and improve fat-free mass in patients with cancer-related weight loss. A comparative phase I bioavailability study of S-pindolol and racemic pindolol was performed to support the development of S-pindolol in cancer cachexia.

View Article and Find Full Text PDF

How antipsychotics work in schizophrenia: a primer on mechanisms.

CNS Spectr

December 2024

Voluntary Clinical Professor of Psychiatry, University of California, San Diego, CA, USA.

Antipsychotics effective for schizophrenia approved prior to 2024 shared the common mechanism of postsynaptic dopamine D receptor antagonism or partial agonism. Positive psychosis symptoms correlate with excessive presynaptic dopamine turnover and release, yet this postsynaptic mechanism improved positive symptoms only in some patients, and with concomitant risk for off-target motor and endocrine adverse effects; moreover, these agents showed no benefit for negative symptoms and cognitive dysfunction. The sole exception was data supporting cariprazine's superiority to risperidone for negative symptoms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!